{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:05:40Z","timestamp":1768853140755,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Melinta Therapeutics."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ijid.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T13:45:57Z","timestamp":1591796757000},"page":"374-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial"],"prefix":"10.1016","volume":"97","author":[{"given":"Sandra","family":"McCurdy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Nenninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Keedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Quintas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2020.06.018_bib0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacteria pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2020.06.018_bib0010","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dku159","article-title":"Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis","volume":"69","author":"Burdet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2020.06.018_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/23120541.00096-2018","article-title":"Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study","volume":"4","author":"Carugati","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ijid.2020.06.018_bib0020","series-title":"Methods for Antimicrobial susceptibility testing for human mycoplasmas; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"10.1016\/j.ijid.2020.06.018_bib0025","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 9th ed. CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijid.2020.06.018_bib0030","series-title":"Performance standards for antimicrobial susceptibility testing; Twenty-eighth informational supplement. CLSI document M100-S28","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.ijid.2020.06.018_bib0035","unstructured":"Delafloxacin USPI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000208611s000lbl.pdf."},{"key":"10.1016\/j.ijid.2020.06.018_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and Safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) Trial","author":"File","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2020.06.018_bib0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00134-002-1304-8","article-title":"Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy","volume":"28","author":"Gacouin","year":"2002","journal-title":"Intensive Care Med"},{"issue":"677","key":"10.1016\/j.ijid.2020.06.018_bib0050","article-title":"Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective","volume":"18","author":"Gramegna","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2020.06.018_bib0055","volume":"vol 68","author":"Heron","year":"2019"},{"key":"10.1016\/j.ijid.2020.06.018_bib0060","series-title":"A Phase-3 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults with Community-acquired Bacterial Pneumonia (DEFINE-CABP)","author":"Horcajada","year":"2020"},{"issue":"5","key":"10.1016\/j.ijid.2020.06.018_bib0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.06.018_bib0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/23.1.37","article-title":"Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions","volume":"23","author":"Liebers","year":"1989","journal-title":"J Antimicrob Chemother"},{"issue":"September(10)","key":"10.1016\/j.ijid.2020.06.018_bib0075","article-title":"Safety of delafloxacin: focus on adverse events of special interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2020.06.018_bib0080","doi-asserted-by":"crossref","first-page":"e00772 17","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and non-susceptible Staphylococcus aureus isolates from two Phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2020.06.018_bib0085","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of Delafloxacin Versus Moxifloxacin Against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijid.2020.06.018_bib0090","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2020.06.018_bib0095","doi-asserted-by":"crossref","first-page":"e00649","DOI":"10.1128\/mSphere.00649-18","article-title":"Culture of clinical specimens reveals extensive diversity of Legionella pneumophila strains in Arizona","volume":"4","author":"Raphael","year":"2019","journal-title":"mSphere"},{"issue":"February(6)","key":"10.1016\/j.ijid.2020.06.018_bib0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.06.018_bib0105","series-title":"Coordinating","article-title":"Cumitech 34, Laboratory Diagnosis of Mycoplasma Infections","author":"Waites","year":"2001"},{"key":"10.1016\/j.ijid.2020.06.018_bib0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2020.06.018_bib0115","doi-asserted-by":"crossref","first-page":"e00968","DOI":"10.1128\/JCM.00968-19","article-title":"Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program","volume":"57","author":"Waites","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.ijid.2020.06.018_bib0120","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1532-5415.2012.04208.x","article-title":"Clinical and economic burden of community-acquired pneumonia in the medicare fee-for-service population","volume":"60","author":"Yu","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ijid.2020.06.018_bib0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13756-019-0576-5","article-title":"Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China","volume":"8","author":"Zhao","year":"2019","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220304550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220304550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:53:56Z","timestamp":1761119636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220304550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":25,"alternative-id":["S1201971220304550"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.06.018","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Melinta Therapeutics. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}